Other News

Zynex Recognized as the Sixth Largest Biotechnology/Bioscience Company in Colorado

ENGLEWOOD, Colo., March 30, 2021 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced the Denver Business Journal has recognized Zynex as the sixth largest Biotechnology/Bioscience public company in Colorado based on number of […]

Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., March 29, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates. Key Business and Financial Updates Completed […]

Physicians In The U.S. Begin Commercial Use Of The GORE® EXCLUDER® Conformable AAA Endoprosthesis With ACTIVE CONTROL System

FLAGSTAFF, Ariz., March 30, 2021 /PRNewswire/ — Today, W. L. Gore & Associates, Inc.  (Gore) announces the first use of the FDA approved GORE® EXCLUDER® Conformable AAA Endoprothesis with ACTIVE CONTROL System in cases outside of clinical trials. Cases were successfully performed by Robert Rhee, M.D. with Mahmoud Almadani, M.D., in Brooklyn, New York and by Gustavo Oderich, M.D. with Naveed Saqib, M.D., in Houston, Texas. The GORE […]

BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology

Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) — Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technology designed to elevate treatments for cardiac arrhythmias Atrial fibrillation is the most common arrhythmia type, affecting over 6 million people in the U.S. and causing […]

Shockwave Provides Update on U.S. Launch of Coronary IVL System

Announces Preliminary Revenue Range for the First Quarter of 2021 SANTA CLARA, Calif., March 30, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced a preliminary forecast revenue range for the first quarter […]

Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering Use of Thykamine™ for the Treatment of Cardiovascular Diseases.

QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent […]

Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which intermediate-risk adult […]

PaceMate™ Closes Series A Financing to Accelerate Growth

BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital healthcare company in compliant cardiac data management, is pleased to announce a recent $8 million Series A investment led by Ballast Point Ventures. PaceMate™’s fully automated, bidirectional EHR-integrated platform—PaceMate™LIVE—is a comprehensive, cloud-native cardiac data management solution, delivering round-the-clock remote monitoring service, customized alerts and […]

Mezzion Announces Re-Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients who have undergone the Fontan Operation for Single Ventricle Heart Disease

Submitted for FDA Priority Review as a Rare Pediatric Disease Product Application SEOUL, South Korea, March 28, 2021 /PRNewswire/ — Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has re-submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of udenafil to improve the exercise capacity of patients […]